Halozyme Therapeutics Inc HALO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
-
Roche Gets FDA Approval for Multiple-Sclerosis Treatment
-
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
-
Halozyme to Present at Upcoming Investor Conferences
-
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
-
Halozyme to Report Second Quarter 2024 Financial and Operating Results
-
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation
Trading Information
- Previous Close Price
- $56.64
- Day Range
- $56.20–58.39
- 52-Week Range
- $32.83–65.53
- Bid/Ask
- $58.30 / $58.50
- Market Cap
- $7.37 Bil
- Volume/Avg
- 1.3 Mil / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 21.17
- Price/Sales
- 8.72
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 3.42%
Company Profile
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 373
- Website
- https://www.halozyme.com
Comparables
Valuation
|
Metric
|
HALO
|
CLDX
|
ACLX
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.17 | — | — |
Price/Book Value | 25.43 | 2.46 | 8.39 |
Price/Sales | 8.72 | 203.98 | 26.81 |
Price/Cash Flow | 15.70 | — | 494.06 |
Price/Earnings
HALO
CLDX
ACLX
Financial Strength
|
Metric
|
HALO
|
CLDX
|
ACLX
|
|---|---|---|---|
Quick Ratio | 5.58 | 29.06 | 5.85 |
Current Ratio | 7.41 | 29.36 | 6.01 |
Interest Coverage | 23.22 | — | −28.35 |
Quick Ratio
HALO
CLDX
ACLX
Profitability
|
Metric
|
HALO
|
CLDX
|
ACLX
|
|---|---|---|---|
Return on Assets (Normalized) | 19.42% | −19.66% | −1.88% |
Return on Equity (Normalized) | 188.75% | −20.83% | −3.31% |
Return on Invested Capital (Normalized) | 22.15% | −20.72% | −7.10% |
Return on Assets
HALO
CLDX
ACLX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ddbztlkwy | Hrtf | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nqbnylr | Fdfczbh | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ydvqrhq | Qrvlrj | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yfqyftktw | Dpnls | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Shtmshk | Lyvv | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Cqgjkwfp | Rmjcd | $28.3 Bil | |||
| Moderna Inc
MRNA
| Qclvzjsm | Kmy | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Lfgswfsyn | Plfr | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Htqtqcg | Thbqr | $13.3 Bil | |||
| Incyte Corp
INCY
| Qszvshgxv | Dhdgjf | $13.0 Bil |
United States